Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Voyager Therapeutics stock price, quote, forecast and news

VYGR
US92915B1061
A143XJ

Price

7.26
Today +/-
+0.20
Today %
+3.08 %
P

Voyager Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Voyager Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Voyager Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Voyager Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Voyager Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Voyager Therapeutics Stock Price History

DateVoyager Therapeutics Price
8/8/20247.26 undefined
8/7/20247.04 undefined
8/6/20248.19 undefined
8/5/20247.97 undefined
8/2/20248.30 undefined
8/1/20248.68 undefined
7/31/20249.19 undefined
7/30/20249.26 undefined
7/29/20249.12 undefined
7/26/20249.27 undefined
7/25/20249.19 undefined
7/24/20248.90 undefined
7/23/20248.86 undefined
7/22/20248.77 undefined
7/19/20248.37 undefined
7/18/20248.43 undefined
7/17/20248.73 undefined
7/16/20249.09 undefined
7/15/20248.96 undefined
7/12/20248.77 undefined
7/11/20248.94 undefined

Voyager Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Voyager Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Voyager Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Voyager Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Voyager Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Voyager Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Voyager Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Voyager Therapeutics’s growth potential.

Voyager Therapeutics Revenue, EBIT and net profit per share

DateVoyager Therapeutics RevenueVoyager Therapeutics EBITVoyager Therapeutics Net Income
2029e70.13 M undefined0 undefined-62.32 M undefined
2028e94.58 M undefined-105.82 M undefined-4.85 M undefined
2027e62.61 M undefined-138.16 M undefined-62.69 M undefined
2026e55.35 M undefined-123.22 M undefined-82.46 M undefined
2025e52.89 M undefined-121.29 M undefined-92.98 M undefined
2024e49.48 M undefined-103.34 M undefined-83.51 M undefined
2023250.01 M undefined122.01 M undefined132.33 M undefined
202240.9 M undefined-50.8 M undefined-46.4 M undefined
202137.4 M undefined-73.6 M undefined-71.2 M undefined
2020171.1 M undefined27.4 M undefined36.7 M undefined
2019104.4 M undefined-51.7 M undefined-43.6 M undefined
20187.6 M undefined-91.1 M undefined-88.3 M undefined
201710.1 M undefined-71.9 M undefined-70.7 M undefined
201614.2 M undefined-41.3 M undefined-40.2 M undefined
201517.3 M undefined-20.3 M undefined-38.3 M undefined
20140 undefined-14.4 M undefined-17.7 M undefined
20130 undefined-3.8 M undefined-3.8 M undefined

Voyager Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0017141071041713740250495255629470
----17.65-28.57-30.001,385.7164.42-78.368.11525.00-80.406.125.7712.7351.61-25.53
-----------------
00000000000000000
-3-14-20-41-71-91-5127-73-50122-103-121-123-138-1050
---117.65-292.86-710.00-1,300.00-49.0415.79-197.30-125.0048.80-210.20-232.69-223.64-222.58-111.70-
-3-17-38-40-70-88-4336-71-46132-83-92-82-62-4-62
-466.67123.535.2675.0025.71-51.14-183.72-297.22-35.21-386.96-162.8810.84-10.87-24.39-93.551,450.00
25.725.725.725.326.832.135.937.337.738.444.57000000
-----------------
Details

Keystats

ⓘ

Revenue and Growth

The Voyager Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Voyager Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (k)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20132014201520162017201820192020202120222023
0.17194.3174.4169.1155.8281.5181.1132.5118.8230.88
00000018.580.70.383.49
0000005001000300964
00000000000
01.31.242.76.54.28.53.454.35
0.18.3195.5178.4171.8162.3304.7197.7136.6124.4319.68
02.83.27.910.312.846.561.555.433.330
00301.41.10.61.90000
00000000000
00000000000
00000000000
00.30.31.51.31.11.72.31.81.51.59
03.133.510.812.714.550.163.857.234.831.6
0.111.4229189.2184.5176.8354.8261.5193.8159.2351.28
022000000000.04
00219.1226295315.6412.2430.3442.3452.7497.51
-3.8-20.8-49.8-90-160.7-269.1-312.6-275.9-347.1-393.5-261.18
00-0.3-0.1-0.3-0.1-0.1-0.1-0.1-0.2-0.05
00000000000
-3.81.2169135.913446.499.5154.395.159236.32
11.60.60.6114.10.60.62.61.6
0.10.63.46.511.59.824.718.419.810.620.02
00.319.96.83.420.847.27.730.659.442.88
2.90000000000
00000000000
42.523.913.915.931.67626.75172.664.51
06.3000000000
00000000000
01.636.539.834.598.9179.280.547.827.750.45
07.936.539.834.598.9179.280.547.827.750.45
410.460.453.750.4130.5255.2107.298.8100.3114.96
0.211.6229.4189.6184.4176.9354.7261.5193.9159.3351.28
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Voyager Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Voyager Therapeutics's financial health and stability.

Assets

Voyager Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Voyager Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Voyager Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Voyager Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20132014201520162017201820192020202120222023
-3-16-29-40-70-88-4336-71-46132
00001223564
00000000000
1156-11-15578-144320-66
03171518302622201618
00000000000
00000000000
-2-1141-42-61-1548-96-53-1277
0-2-1-5-3-4-7-12-1-2-3
0-3-19447-326-9011365-7-141
00-19352030-8212567-4-138
00000000000
20000000000
02210405948030133
22217705948030133
007200000000
00000000000
06245-515391912-18-30
-2.73-14.9140.27-47.51-65.34-20.240.95-108.82-55.14-1574.66
00000000000

Voyager Therapeutics stock margins

The Voyager Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Voyager Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Voyager Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Voyager Therapeutics's sales revenue. A higher gross margin percentage indicates that the Voyager Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Voyager Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Voyager Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Voyager Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Voyager Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Voyager Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Voyager Therapeutics Margin History

Voyager Therapeutics Gross marginVoyager Therapeutics Profit marginVoyager Therapeutics EBIT marginVoyager Therapeutics Profit margin
2029e0 %0 %-88.87 %
2028e0 %-111.88 %-5.13 %
2027e0 %-220.66 %-100.12 %
2026e0 %-222.64 %-148.98 %
2025e0 %-229.34 %-175.82 %
2024e0 %-208.85 %-168.78 %
20230 %48.8 %52.93 %
20220 %-124.21 %-113.45 %
20210 %-196.79 %-190.37 %
20200 %16.01 %21.45 %
20190 %-49.52 %-41.76 %
20180 %-1,198.68 %-1,161.84 %
20170 %-711.88 %-700 %
20160 %-290.85 %-283.1 %
20150 %-117.34 %-221.39 %
20140 %0 %0 %
20130 %0 %0 %

Voyager Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Voyager Therapeutics earnings per share therefore indicates how much revenue Voyager Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Voyager Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Voyager Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Voyager Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Voyager Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Voyager Therapeutics Revenue, EBIT and net profit per share

DateVoyager Therapeutics Sales per ShareVoyager Therapeutics EBIT per shareVoyager Therapeutics Earnings per Share
2029e1.29 undefined0 undefined-1.15 undefined
2028e1.74 undefined0 undefined-0.09 undefined
2027e1.15 undefined0 undefined-1.15 undefined
2026e1.02 undefined0 undefined-1.52 undefined
2025e0.97 undefined0 undefined-1.71 undefined
2024e0.91 undefined0 undefined-1.54 undefined
20235.61 undefined2.74 undefined2.97 undefined
20221.07 undefined-1.32 undefined-1.21 undefined
20210.99 undefined-1.95 undefined-1.89 undefined
20204.59 undefined0.73 undefined0.98 undefined
20192.91 undefined-1.44 undefined-1.21 undefined
20180.24 undefined-2.84 undefined-2.75 undefined
20170.38 undefined-2.68 undefined-2.64 undefined
20160.56 undefined-1.63 undefined-1.59 undefined
20150.67 undefined-0.79 undefined-1.49 undefined
20140 undefined-0.56 undefined-0.69 undefined
20130 undefined-0.15 undefined-0.15 undefined

Voyager Therapeutics business model

Voyager Therapeutics Inc is a biopharmaceutical company specializing in the development of gene therapy products. The company was founded in 2013 in Cambridge, Massachusetts. The main business model of Voyager Therapeutics involves the development, manufacturing, and marketing of gene therapy products. The company specializes in nervous system and ocular therapies and works closely with leading scientists and clinical institutes. Voyager Therapeutics has several business and research divisions: the Parkinson's Disease division, the Huntington's Disease division, and the Amyotrophic Lateral Sclerosis (ALS) division. The Parkinson's Disease division of Voyager Therapeutics focuses on developing gene therapies for the treatment of Parkinson's disease. The products being developed in this division aim to increase the amount of dopamine in the brain to alleviate the symptoms of Parkinson's disease. Parkinson's patients often suffer from symptoms such as tremors, stiffness, and lack of movement. The Huntington's Disease division of Voyager Therapeutics specializes in developing gene therapy products for the treatment of Huntington's disease. This disease is a hereditary condition that leads to the accumulation of toxic proteins in the brain, eventually causing neurological symptoms such as slow thinking and tremors. The ALS division of Voyager Therapeutics focuses on developing gene therapies for the treatment of Amyotrophic Lateral Sclerosis (ALS). ALS is a neurodegenerative disease in which nerve cells in the brain and spinal cord degenerate, leading to muscle weakness and atrophy. Voyager Therapeutics works closely with various institutions and companies to advance its research and development. Key collaboration partners include Sanofi Genzyme, Abbvie, Neurocrine Biosciences, and the University of Massachusetts Medical School. Some of Voyager Therapeutics' key products are currently in clinical trials or in development. The company is working on developing gene therapies for the treatment of Parkinson's disease, Huntington's disease, and ALS. One example of a product developed by Voyager Therapeutics is VY-AADC, a gene therapy for the treatment of Parkinson's disease. It is currently being tested in Phase 2 clinical trials. Another example is VY-HTT01, a gene therapy for the treatment of Huntington's disease. VY-HTT01 is currently in the preclinical development phase and is expected to be tested in clinical trials in the coming years. Overall, Voyager Therapeutics has a promising future in the gene therapy industry. The company has already achieved significant successes and continues to work intensively on developing new therapies to help people with neurological disorders. Voyager Therapeutics is one of the most popular companies on Eulerpool.com.

Voyager Therapeutics SWOT Analysis

Strengths

Voyager Therapeutics Inc has a strong research and development pipeline, allowing them to develop innovative therapies for neurological diseases.

The company has experienced and talented scientists and researchers who possess specialized knowledge in gene therapy, enabling them to stay at the forefront of the industry.

Voyager Therapeutics Inc has established strategic partnerships and collaborations with reputable organizations, which provides access to additional resources, expertise, and funding.

Weaknesses

The company is heavily reliant on the success of its research and development efforts, and any setbacks or delays in clinical trials could negatively impact its financial position and investor confidence.

Voyager Therapeutics Inc has limited marketing and commercialization experience, which may pose challenges when it comes to effectively promoting and selling their therapies once approved.

The company's dependency on external funding sources, such as grants and partnerships, makes it vulnerable to changes in the availability and terms of such funding.

Opportunities

The increasing prevalence of neurological disorders presents a significant market opportunity for Voyager Therapeutics Inc to develop and market their therapies.

Continuous advancements in gene therapy and the exploration of new technologies provide the company with a chance to further enhance and expand their treatment options.

Expansion into international markets can grant Voyager Therapeutics Inc access to a broader patient population and potentially increase their revenue streams.

Threats

Regulatory challenges and stringent approval processes pose a threat to Voyager Therapeutics Inc's ability to bring their therapies to market in a timely manner.

Competition from larger pharmaceutical companies with more financial resources and established market presence may limit Voyager Therapeutics Inc's market share and ability to gain traction.

Changes in healthcare policies and reimbursement models could impact the affordability and accessibility of Voyager Therapeutics Inc's therapies, making it difficult to generate revenue.

Voyager Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Voyager Therapeutics historical P/E ratio, EBIT, and P/S ratio.

Voyager Therapeutics shares outstanding

The number of shares was Voyager Therapeutics in 2023 — This indicates how many shares 44.569 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Voyager Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Voyager Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Voyager Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Voyager Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Voyager Therapeutics.

Voyager Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.42 -0.18  (56.91 %)2024 Q2
3/31/2024-0.45 -0.2  (55.44 %)2024 Q1
12/31/2023-0.29 1.25  (524.74 %)2023 Q4
9/30/2023-0.59 -0.59  (0.49 %)2023 Q3
6/30/2023-0.58 -0.51  (12.05 %)2023 Q2
3/31/20230.79 2.94  (273.52 %)2023 Q1
12/31/2022-0.56 -0.61  (-9.3 %)2022 Q4
9/30/2022-0.32 0.45  (239.1 %)2022 Q3
6/30/2022-0.32 -0.5  (-54.37 %)2022 Q2
3/31/2022-0.35 -0.56  (-59.45 %)2022 Q1
1
2
3
4

Eulerpool ESG Scorecard© for the Voyager Therapeutics stock

Eulerpool World ESG Rating (EESG©)

42/ 100

🌱 Environment

42

👫 Social

66

🏛️ Governance

17

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety❌
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Voyager Therapeutics list of shareholders

%
Name
Stocks
Change
Date
7.79 % Armistice Capital LLC4,236,00058,00012/31/2023
7.08 % EcoR1 Capital, LLC3,851,507012/31/2023
4.65 % The Vanguard Group, Inc.2,529,66847,71112/31/2023
4.08 % BlackRock Institutional Trust Company, N.A.2,221,266144,95812/31/2023
2.38 % Farallon Capital Management, L.L.C.1,292,000012/31/2023
15.77 % Neurocrine Biosciences Inc8,575,3164,395,5882/23/2023
1.79 % T. Rowe Price Associates, Inc.976,285-169,77112/31/2023
1.71 % Dimensional Fund Advisors, L.P.932,231153,29112/31/2023
1.25 % Geode Capital Management, L.L.C.678,87831,93312/31/2023
1.18 % AQR Capital Management, LLC639,287440,46512/31/2023
1
2
3
4
5
...
10

Voyager Therapeutics Executives and Management Board

Dr. Alfred Sandrock65
Voyager Therapeutics President, Chief Executive Officer, Director (since 2022)
Compensation 7.4 M
Mr. Peter Pfreundschuh54
Voyager Therapeutics Chief Financial Officer
Compensation 1.79 M
Mr. Michael Higgins60
Voyager Therapeutics Independent Chairman of the Board (since 2015)
Compensation 757,532
Dr. Glenn Pierce67
Voyager Therapeutics Independent Director (since 2017)
Compensation 242,342
Dr. Catherine Mackey67
Voyager Therapeutics Independent Director
Compensation 206,602
1
2
3

Most common questions regarding Voyager Therapeutics

What values and corporate philosophy does Voyager Therapeutics represent?

Voyager Therapeutics Inc is a pioneering company dedicated to developing transformative gene therapies for severe neurological diseases. With a strong commitment to patients, Voyager Therapeutics strives to deliver innovative treatments that can significantly improve their quality of life. The company's corporate philosophy is centered around integrity, innovation, and collaboration. By combining cutting-edge science, advanced technologies, and a multidisciplinary approach, Voyager Therapeutics aims to unlock the potential of gene therapy and create new opportunities for patients suffering from neurological disorders. Through their unwavering dedication and expertise, Voyager Therapeutics is poised to revolutionize the field of gene therapy and address unmet medical needs.

In which countries and regions is Voyager Therapeutics primarily present?

Voyager Therapeutics Inc is primarily present in the United States.

What significant milestones has the company Voyager Therapeutics achieved?

Voyager Therapeutics Inc has achieved significant milestones in the field of gene therapy. The company has successfully developed and advanced several programs aimed at treating severe neurological diseases. One notable accomplishment includes the initiation of a phase 2 clinical trial for VY-AADC, a potential treatment for Parkinson's disease. Voyager also entered into a collaboration with AbbVie to develop gene therapies for Alzheimer's disease, tauopathies, and severe neurological diseases. Additionally, Voyager has forged partnerships with leading academic institutions and organizations, further solidifying its position as a prominent player in the field of gene therapy.

What is the history and background of the company Voyager Therapeutics?

Voyager Therapeutics Inc is a biopharmaceutical company focused on developing gene therapies for severe neurological diseases. Founded in 2013, the company aims to address the significant unmet need in the field of neurodegenerative disorders. Voyager Therapeutics leverages its expertise in gene therapy to deliver transformative treatments for diseases such as Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS). The company collaborates with renowned institutions and has a robust pipeline of potential therapies. With a commitment to improving patients' lives, Voyager Therapeutics continues to make advancements in the field of gene therapy and neurology.

Who are the main competitors of Voyager Therapeutics in the market?

The main competitors of Voyager Therapeutics Inc in the market include companies such as Axovant Gene Therapies Ltd, uniQure N.V., and Solid Biosciences Inc.

In which industries is Voyager Therapeutics primarily active?

Voyager Therapeutics Inc is primarily active in the biotechnology industry.

What is the business model of Voyager Therapeutics?

The business model of Voyager Therapeutics Inc. focuses on developing gene therapies for severe neurological diseases. By harnessing the power of the central nervous system's ability to produce proteins, Voyager aims to address genetic deficiencies that cause these diseases. The company utilizes viral vectors to deliver therapeutic genes to the targeted areas of the brain, aiming to provide long-term benefits to patients. Voyager's expertise lies in the development of innovative treatments for Parkinson's disease, Huntington's disease, and other genetic disorders. Through its gene therapy platform, Voyager Therapeutics Inc. strives to improve the lives of individuals living with these debilitating conditions.

What is the P/E ratio of Voyager Therapeutics 2024?

The Voyager Therapeutics P/E ratio is -3.87.

What is the P/S ratio of Voyager Therapeutics 2024?

The Voyager Therapeutics P/S ratio is 6.54.

What is the AlleAktien quality score of Voyager Therapeutics?

The AlleAktien quality score for Voyager Therapeutics is 5/10.

What is the revenue of Voyager Therapeutics 2024?

The expected Voyager Therapeutics revenue is 49.48 M USD.

How high is the profit of Voyager Therapeutics 2024?

The expected Voyager Therapeutics profit is -83.51 M USD.

What is the business model of Voyager Therapeutics

Voyager Therapeutics Inc. is a gene therapy company focused on developing therapies for genetic diseases. The company's business model is based on the development and commercialization of gene therapies for severe and rare diseases. By focusing on gene therapy, the company is aligned with developing effective treatments and enjoys a competitive advantage as the gene therapy market is still relatively new. Voyager Therapeutics has three types of gene therapies in its pipeline, including adeno-associated virus (AAV) gene therapies, ex-vivo gene therapies, and therapies for neurodegenerative diseases. In addition to developing therapies, the company also offers services such as clinical trials and gene therapy production. Voyager Therapeutics aims to make gene therapy the standard for treating severe diseases and plans to expand into other industries through licensing its technology and collaborating with other companies. The company has partnerships with major biotech and pharmaceutical companies to access resources and improve its scientific and technical capabilities. Overall, Voyager Therapeutics' business model aims to develop and market gene therapies to address unmet medical needs in rare and severe diseases, while also expanding its presence in other industries.

What is the Voyager Therapeutics dividend?

Voyager Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Voyager Therapeutics pay dividends?

The dividend cannot currently be calculated for Voyager Therapeutics or the company does not pay out a dividend.

What is the Voyager Therapeutics ISIN?

The ISIN of Voyager Therapeutics is US92915B1061.

What is the Voyager Therapeutics WKN?

The WKN of Voyager Therapeutics is A143XJ.

What is the Voyager Therapeutics ticker?

The ticker of Voyager Therapeutics is VYGR.

How much dividend does Voyager Therapeutics pay?

Over the past 12 months, Voyager Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Voyager Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Voyager Therapeutics?

The current dividend yield of Voyager Therapeutics is .

When does Voyager Therapeutics pay dividends?

Voyager Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Voyager Therapeutics?

Voyager Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Voyager Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Voyager Therapeutics located?

Voyager Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Voyager Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Voyager Therapeutics from 8/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/9/2024.

When did Voyager Therapeutics pay the last dividend?

The last dividend was paid out on 8/9/2024.

What was the dividend of Voyager Therapeutics in the year 2023?

In the year 2023, Voyager Therapeutics distributed 0 USD as dividends.

In which currency does Voyager Therapeutics pay out the dividend?

The dividends of Voyager Therapeutics are distributed in USD.

All fundamentals about Voyager Therapeutics

Our stock analysis for Voyager Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Voyager Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.